Supporting this, Taddei and colleagues reported that in a cohort of 367 Ashkenazi Jewish GD patients (54% homozygous for the N370S GBA1 mutation), long-term follow-up revealed heightened risks of both cancer in general and hematologic malignancies in particular [31]. Here, GBA1 is linked to hematologic disorder.